Blood Reviews
Volume 17, Issue 1 , Pages 25-31 , March 2003

Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma

  • Bertrand Coiffier

      Affiliations

    • Corresponding Author InformationCorrespondence to: Tel.: +33-478-86-1194, Fax: +33-478-86-6566

References 

  1. Grillo-Lopez AJ, White CA, Varns C, et al.  Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 1999;26:66–73
  2. Grossbard ML, Fidias P, Kinsella J, et al.  Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Brit. J. Haematol. 1998;102:509–515
  3. Kaminski MS, Zasadny KR, Francis IR, et al.  Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 1996;14:1974–1981
  4. Witzig TE, White CA, Wiseman GA, et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 1999;17:3793–3803
  5. Maloney DG, Liles TM, Czerwinski DK, et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–2466
  6. Maloney DG, Grillolopez AJ, Bodkin DJ, et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J. Clin. Oncol. 1997;15:3266–3274
  7. Foran JM, Rohatiner AZS, Coiffier B, et al.  Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. J. Clin. Oncol. 1999;17:546–553
  8. Coiffier B, Haioun C, Ketterer N, et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood. 1998;92:1927–1932
  9. Demidem A, Lam T, Alas S, et al.  Chimeric anti-CD20 (Idec-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 1997;12:177–186
  10. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644–1652
  11. Shan DM, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 2000;48:673–683
  12. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392–1398
  13. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–5144
  14. Kreitman RJ, Wilson WH, Bergeron K, et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 2001;345:241–247
  15. Dearden CE, Matutes E, Cazin B, et al.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–1726
  16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998;16:2825–2833
  17. Kaminski MS, Zelenetz AD, Press OW, et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J. Clin. Oncol. 2001;19:3918–3928
  18. Gordon LI, Witzig TE, Emmanouilides CE, et al.  90Y ibritumomab (Zevalin) in aggressive non-Hodgkin’s lymphoma: analysis of response and toxicity. Proc. Asco. 2002;21:266a
  19. Foran JM, Rohatiner AZS, Cunningham D, et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. 2000;18:317–324
  20. Foran JM, Cunningham D, Coiffier B, et al.  Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann. Oncol. 2000;11:117–121
  21. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 1982;49:2112–2135
  22. Pan D, Moskowitz CH, Zelenetz AD, et al.  Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin’s lymphoma in the post-transplant setting. Blood. 2000;96:
  23. Lundin J, Kimby E, Bjorkholm M, et al.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768–773
  24. Keating MJ, Flinn I, Jain V, et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561
  25. Uppenkamp M, Engert A, Diehl V, et al.  Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin’s lymphomas: a multicenter phase I/II study. Ann. Hematol. 2002;81:26–32
  26. Keating MJ, Cazin B, Coutre S, et al.  Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol. 2002;20:205–213
  27. Leonard JP, Coleman M, Matthews JC, et al.  Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin’s lymphoma: preliminary response data. Proc. ASCO. 2002;21:266a
  28. Witzig TE, Flinn IW, Gordon LI, et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J. Clin. Oncol. 2002;20:3262–3269
  29. Witzig TE, White CA, Wiseman GA, et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 1999;17:3793–3803
  30. Vose JM, Wahl RL, Saleh M, et al.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J. Clin. Oncol. 2000;18:1316–1323
  31. Witzig TE, Gordon LI, Cabanillas F, et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 2002;20:2453–2463
  32. Czuczman MS, Grillo-Lopez AJ, White CA, et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999;17:268–276
  33. Czuczman MS, Fallon A, Mohr A, et al.  Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin. Oncol. 2002;29:36–40
  34. Howard OM, Gribben JG, Neuberg DS, et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 2002;20:1288–1294
  35. Romaguera JE, Dang NH, Hagemeister FB, et al.  Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL). Blood. 2000;96:733a
  36. Vose JM, Link BK, Grossbard ML, et al.  Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol. 2001;19:389–397
  37. Kewalramani T, Zelenetz A, Bertino J, et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy. Blood 2001
  38. Coiffier B, Lepage E, Brière J, et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med. 2002;346:235–242
  39. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987–994
  40. Hiddemann W, Forstpointner R, Fiedler F, et al. The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL). Results of a prospective randomized comparison of the German low grade study group (GLSG). Blood 2001
  41. Press OW, Eary JF, Gooley T, et al.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942
  42. Ghielmini M, Schmite SFH, Cogliatti SB, et al.  Maintenance treatment with 2-montly rituximab after standard weekly×4 rituximab induction significantly improves efent-free survival in patients with follicular lymphoma. Ann. Oncol. 2002;13(Suppl 2):38
  43. Leonard JP, Link BK. Immunotherapy of non-Hodgkin’s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol. 2002;29:81–86
  44. Gordon LI, Witzig TE, Wiseman GA, et al.  Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin’s lymphoma. Semin. Oncol. 2002;29:87–92
  45. Kaminski MS, Estes J, Zasadny KR, et al.  Radioimmunotherapy with iodine I-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266
  46. Olsen E, Duvic M, Frankel A, et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 2001;19:376–388
  47. Coiffier B. Diffuse large cell lymphoma. Curr. Opin. Oncol. 2001;13:325–334

PII: S0268-960X(02)00059-0

Blood Reviews
Volume 17, Issue 1 , Pages 25-31 , March 2003

Article Tools

* Image Usage & Resolution